On November 11, 2026 Tempus AI, Inc. (NASDAQ: TEM) reported that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This research leverages Tempus’ expansive, de-identified multimodal library, which includes a cohort of 45,085 real-world patients across 615 rare and ultra-rare cancer types. Within this comprehensive repository, sarcomas are among the most well-represented cancer types. This deep data foundation directly enabled the clinical findings being presented at CTOS, demonstrating the power of comprehensive multimodal profiling—including DNA matched tumor/normal sequencing, whole transcriptomic analysis, and digital pathology informatics—to reveal actionable insights.

"In rare diseases, such as sarcoma, small patient datasets make uncovering insights exceptionally challenging, which is where Tempus’ robust dataset brings critical value," said Ezra Cohen M.D., Chief Medical Officer of Oncology at Tempus. "Importantly, Tempus is dedicated through its Orphan Disease Program to providing solutions to the inherent barriers in rare cancers, and to helping physicians develop and tailor therapies more precisely."

Oral Presentations

Thursday, November 19, 2026 | 2:15 PM – 3:15 PM KST

Melanoma-Associated Antigen A4 (MAGE-A4) mRNA Expression and Tumor Immune Micro-Environment (TIME) as Biomarkers in Sarcoma: A Real-World Clinicogenomic Study
Friday, November 20, 2026 | 4:15 PM – 5:15 PM KST

Distinct DNA Damage Response (DDR) Transcriptional Signature is Enriched in a Subset of SDH-Deficient GIST: Implications for Temozolomide Sensitivity
Transcriptomic Subtyping of 1,490 GIST Patients Identifies Prognostic Risk Groups Superior to Clinical and Molecular Variables
Poster Presentations

Transcriptional Programs Associated with Response to Pazopanib in Metastatic Bone and Soft Tissue Sarcoma
Molecular and Genomic Characteristics of Desmoplastic Small Round Cell Tumor
Improving Germline Variant Detection in Sarcoma via Matched Tumor/Normal Sequencing: A Real-World Analysis of 9,025 Patients

(Press release, Tempus, NOV 11, 2026, View Source [SID1234674622])